Dr Baselga speaks with ecancer at AACR 2018 about results from a phase I basket study of taselisib to treat locally advanced or metastatic solid tumours harbouring a PIK3CA mutation.
He highlights how these mutations occur in a host of sites throughout the body.
Dr Baslega also describes results from the development of a cell-free DNA assay, allowing for early detection and monitoring treatment response.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
[ Ссылка ]
Ещё видео!